36 articles for G Wishart
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.
Biofocus
Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors.
Merck Research Laboratories
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Biofocus
Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.
Msd
The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
Msd
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
Msd
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
Merck Research Laboratories
The discovery and SAR of indoline-3-carboxamides--a new series of 5-HT6 antagonists.
Schering-Plough Research Institute
Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Merck Research Laboratories
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.
Merck Research Laboratories
Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
Merck Research Laboratories
Rapid access towards follow-up NOP receptor agonists using a knowledge based approach.
Schering-Plough Research Institute
Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties.
Organon Laboratories
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors.
Nodthera
Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists.
Organon Laboratories
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
Charles River
Discovery of ONO-8590580: A novel, potent and selective GABA
Charles River Discovery Research Services
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.
Chdi Management/Chdi Foundation
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Charles River Discovery (Previously Biofocus)
Structure-activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties.
Organon Laboratories
Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
Oblique Therapeutics
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
Mission Therapeutics
Azepine derivatives as 5-HT7 receptor modulators
Korea Institute of Science and Technology
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
Targeting Bacterial Nitric Oxide Synthase with Aminoquinoline-Based Inhibitors.
University of California Irvine
Harnessing Enzymatic Promiscuity in Myxochelin Biosynthesis for the Production of 5-Lipoxygenase Inhibitors.
Hans Knöll Institute